A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


November 2, 2012

Brief Treatment Interruptions for Cure Studies Are Safe, Well-Tolerated

A new study has shown that short treatment interruptions of antiretroviral (ARV) regimens are both safe and well-tolerated among people with HIV. This is good news for scientists pursuing functional cures because they can use such windows to study novel agents that would suppress the virus without an ARV regimen. University of Minnesota researchers presented their findings as a poster abstract at the IDWeek 2012 meeting in San Diego. They studied 14 HIV-positive people with a CD4 count above 350 and an undetectable viral load, all of whom were on stable ARV regimens. After stopping the subjects’ HIV medications, the researchers carefully monitored their CD4 counts and viral loads until HIV RNA was detectable in the blood, at which point the researchers took samples of the HIV reservoir, performed a genotyping test and then reinitiated ARVs. The average study participant took two weeks to reach a detectable viral load and another two weeks to reach full viral suppression once again. All subjects reached virologic suppression. None saw their CD4 levels change significantly; none suffered physical symptoms with the viral load’s return; and none developed drug-resistance or experienced virologic failure.

To read the poster abstract, click here.

Search: HIV, cure, cure research, short treatment interruptions, STI, antiretroviral, ARV, CD4, regimen, virologic suppression, genotyping test, RNA, Unniversity of Minnesota, IDWeek 2012, San Diego.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.